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Brief Clinical Reportsnot to place the LVAD using bivalirudin or any other direct
thrombin inhibitors because this is associated with poten-
tially lethal bleeding complications.3 Some centers have re-
ported the use of unfractionated heparin and concomitant
potent platelet inhibitors for CPB in the setting of HIT. How-
ever, this approach has not been adopted at our institution.
The use of plasmapheresis for HIT is not a novel concep-
tion. Few studies have reported using plasma exchange
in the management of HIT with thrombosis.4 However, the
surgical literature contains only 1 case report in which
plasmapheresis was successfully used preoperatively in
a HIT-positive patient who required coronary artery bypass
grafting under CPB with heparin.5 To our knowledge, this is
the first reported case of plasmapheresis for a HIT-positive
patient requiring an LVAD.
This isolated experience suggests that plasmapheresis
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e58 The Journal of Thoracic and Cardiovascular SurgHIT-negative status. This allows for the patient to safely
undergo cardiac surgery with CPB using systemic heparin-
ization. The more widespread use of this strategy should
be corroborated in a larger patient population.References
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AustraliaHemophagocytic syndrome (HPS) is a rare but occasionally
life-threatening complication after solid organ transplanta-
tion.1,2 This syndrome is characterized by phagocytizing
histiocytes that infiltrate tissues and phagocytize blood
elements and their precursors. The cause of this syndrome
is unknown.3 The development of HPS has been associated
with an uncontrolled excessive inflammatory response, and
the timely initiation of potentially life-saving therapy with
immunoglobulins and steroids is mandatory. Nonetheless,
the reported prognosis of this syndrome remains poor.1-3
There is no published information regarding HPS in lung
transplantation.We report a case of severe HPS related to Pseudomonas
infection in a lung transplant recipient.CLINICAL SUMMARY
A living-donor single lobar lung transplant was performed
for a patient with pulmonary veno-occlusive disease. The
primary immunosuppression consisted of 2 single doses of
basiliximab, daily doses of methylprednisolone, followed
by maintenance immunosuppression with tacrolimus (target
trough level: 10–15 ng/mL), mycophenolate mofetil, and
prednisolone. Results of blood tests for hepatitis C virus,
hepatitis B virus, cytomegalovirus, and Epstein–Barr virus
of the donor and the recipient were negative.
Pancytopenia (hemoglobin 8.3 g/dL, platelets 53 104/mL,
and neutrophils 0.6 3 103/mL) was first noted as a clinical
problem 8weeks after transplant (Figure 1). Low-grade fever
and mild splenomegaly were present. Elevated levels of
interleukin-2 receptor (2355 U/mL [normal range< 650]),
ferritin (6338 ng/mL [<138]), triglycerides (193 mg/dL
[<150]), aspartate aminotransferase (48 IU/L [<35]), alanine
aminotransferase (73 IU/L [<42]), alkaline phosphatase
(630 IU/L [<360]), g-glutanyl transferase (182 IU/L
[<40]), and fibrinogen (420 mg/dL [<390]) were also noted.
Bone marrow aspiration revealed massive hemophagocyticery c September 2010
FIGURE 1. Leukopenia and thrombocytopenia markedly improved after
initiation of sirolimus (SRL), basiliximab, immunoglobulin, and pulsed-
steroid therapy. FK, Tacrolimus; MMF, mycophenolate mofetil.
FIGURE 2. Light microscopic image of bone marrow aspiration showing
macrophages containing blood cells in their cytoplasm.
Brief Clinical Reportsreaction (Figure 2). Sources of infection were sought to
explain this possible HPS. Pseudomonas producing met-
allo-b-lactamase, previously detected as an asymptomatic
presumed colonizing organism in the native lung, was now
noted to be causing a new problem of bronchitis/mild
pneumonitis with a simultaneous and persistent increasing
elevation of the white blood cell count (from 15 to
233 103/mL). After discontinuation of calcineurin inhibitor
and after initiation of sirolimus, basiliximab, immunoglobu-
lin, and steroid pulse therapy, leukopenia/thrombocytopenia
markedly improved, with the patient recovering from the
HPS. After a short period of stability, Pseudonomas pneumo-
nia worsened. Despite aggressive antibiotic therapy, includ-
ing imipenem/cilastatin, aztreonam, tazobactam/piperacillin,
and polymyxin as a last resort, 4 weeks later this now
multidrug-resistant Pseudomonas aeruginosa caused a fatal
bacterial septicemia.
DISCUSSION
HPS is a rare but significant complication after solid organ
transplantation. To our knowledge, this is the first report of
HPS in lung transplantation.
HPS is a sepsis-associated condition characterized by
a highly stimulated but miss-directed immune response.
This syndrome is often caused by exogenous agents (infec-
tious organisms, toxins) and endogenous products (tissue
damage, metabolic products), and it is associated with pan-
cytopenia, coagulopathy, and liver dysfunction.3When a pa-
tient has fever, pancytopenia, and splenomegaly, HPS
should be considered.3 The clinical and laboratory diagnos-
tic criteria are as follows: (1) fever, (2) splenomegaly, (3) cy-
topenia of 2 cell lines or more (hemoglobin, platelets, andneutrophils), (4) hypertriglyceridemia and/or hypofibrinoge-
nemia, (5) elevated ferritin, (6) elevated interleukin-2 recep-
tor, (7) decreased natural killer cell activity, and (8)
hemophagocytosis in bone marrow (>5/8 criteria).3 Immu-
nocompromised patients are thought to be more prone to
the development of HPS, probably because it is triggered
by opportunistic infections. According to the largest case se-
ries of kidney transplant recipients, the incidence of HPS
was 0.4% with a mortality of 47%.1 In the current case,
no viral or new bacterial infections were detected after trans-
plant; however, the persistence of multidrug-resistant Pseu-
domonas in the recipient airways may well have provided
the initial infectious stimulus. In general, in HPS hyperin-
flammation can be treated with steroid therapy and calci-
neurin inhibitor blocking the T-lymphocyte response.
Reduction of immunosuppression and immunoglobulin
infusion helping to control the infection and will block
B-lymphocyte responses.1,2 In the current case, sirolimus,
basiliximab, immunoglobulin, and steroid pulse therapy
were successfully used to downregulate the response of
both B and T cells to the overproduction of interleukin 2.
In conclusion, HPS is a significant diagnostic and thera-
peutic challenge in lung transplantation. Awareness of the
diagnostic criteria of this rare, but potentially fatal, compli-
cation is important if timely therapies are to be initiated.
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